Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 35 studies | 41% ± 18% | |
fibroblast | 22 studies | 37% ± 20% | |
smooth muscle cell | 18 studies | 32% ± 18% | |
endothelial cell of lymphatic vessel | 13 studies | 32% ± 9% | |
endothelial cell of artery | 12 studies | 46% ± 17% | |
vein endothelial cell | 12 studies | 45% ± 24% | |
capillary endothelial cell | 11 studies | 37% ± 14% | |
pericyte | 10 studies | 26% ± 7% | |
endothelial cell of vascular tree | 9 studies | 32% ± 10% | |
respiratory goblet cell | 6 studies | 29% ± 17% | |
myofibroblast cell | 6 studies | 34% ± 24% | |
alveolar macrophage | 5 studies | 20% ± 3% | |
club cell | 5 studies | 25% ± 7% | |
cardiac muscle cell | 5 studies | 30% ± 3% | |
hepatocyte | 4 studies | 38% ± 31% | |
connective tissue cell | 4 studies | 51% ± 28% | |
epithelial cell | 4 studies | 31% ± 6% | |
duct epithelial cell | 3 studies | 21% ± 6% | |
macrophage | 3 studies | 25% ± 3% | |
glomerular endothelial cell | 3 studies | 37% ± 1% | |
adventitial cell | 3 studies | 31% ± 8% | |
endocardial cell | 3 studies | 50% ± 7% | |
endothelial cell of sinusoid | 3 studies | 43% ± 11% | |
secretory cell | 3 studies | 31% ± 9% | |
luminal cell of prostate epithelium | 3 studies | 18% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 95683.75 | 578 / 578 | 92% | 158.68 | 1066 / 1155 |
prostate | 93% | 38592.85 | 227 / 245 | 97% | 184.34 | 486 / 502 |
liver | 92% | 55844.05 | 207 / 226 | 92% | 127.77 | 372 / 406 |
bladder | 95% | 47819.33 | 20 / 21 | 74% | 118.16 | 373 / 504 |
uterus | 99% | 77544.25 | 169 / 170 | 69% | 112.67 | 319 / 459 |
kidney | 74% | 20664.44 | 66 / 89 | 86% | 191.58 | 778 / 901 |
stomach | 53% | 13019.15 | 191 / 359 | 93% | 137.28 | 265 / 286 |
esophagus | 69% | 22203.93 | 1003 / 1445 | 76% | 101.21 | 139 / 183 |
intestine | 58% | 9498.27 | 562 / 966 | 87% | 98.28 | 458 / 527 |
thymus | 59% | 11565.49 | 388 / 653 | 69% | 66.60 | 420 / 605 |
adrenal gland | 73% | 11793.88 | 188 / 258 | 46% | 33.18 | 106 / 230 |
pancreas | 15% | 2174.78 | 48 / 328 | 92% | 276.63 | 163 / 178 |
ovary | 38% | 9451.06 | 68 / 180 | 68% | 81.95 | 294 / 430 |
blood vessel | 100% | 152660.57 | 1335 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 72478.32 | 841 / 861 | 0% | 0 | 0 / 0 |
breast | 36% | 6111.54 | 165 / 459 | 60% | 37.18 | 672 / 1118 |
spleen | 73% | 11105.42 | 176 / 241 | 0% | 0 | 0 / 0 |
skin | 11% | 2020.83 | 204 / 1809 | 52% | 39.09 | 246 / 472 |
lymph node | 0% | 0 | 0 / 0 | 62% | 40.14 | 18 / 29 |
adipose | 55% | 11210.60 | 667 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 44% | 20.64 | 20 / 45 |
brain | 11% | 1487.75 | 297 / 2642 | 29% | 12.00 | 202 / 705 |
muscle | 33% | 7895.68 | 263 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 11% | 4.13 | 9 / 80 |
peripheral blood | 1% | 52.11 | 5 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1903351 | Biological process | cellular response to dopamine |
GO_0018149 | Biological process | peptide cross-linking |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_0060445 | Biological process | branching involved in salivary gland morphogenesis |
GO_0043547 | Biological process | positive regulation of GTPase activity |
GO_2000425 | Biological process | regulation of apoptotic cell clearance |
GO_0032471 | Biological process | negative regulation of endoplasmic reticulum calcium ion concentration |
GO_0014046 | Biological process | dopamine secretion |
GO_1904015 | Biological process | cellular response to serotonin |
GO_0050769 | Biological process | positive regulation of neurogenesis |
GO_0018277 | Biological process | protein deamination |
GO_0045785 | Biological process | positive regulation of cell adhesion |
GO_1903672 | Biological process | positive regulation of sprouting angiogenesis |
GO_0006338 | Biological process | chromatin remodeling |
GO_0051561 | Biological process | positive regulation of mitochondrial calcium ion concentration |
GO_0043277 | Biological process | apoptotic cell clearance |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0071314 | Biological process | cellular response to cocaine |
GO_0006508 | Biological process | proteolysis |
GO_0051057 | Biological process | positive regulation of small GTPase mediated signal transduction |
GO_0010467 | Biological process | gene expression |
GO_0060348 | Biological process | bone development |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0060662 | Biological process | salivary gland cavitation |
GO_0005886 | Cellular component | plasma membrane |
GO_0000786 | Cellular component | nucleosome |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0031012 | Cellular component | extracellular matrix |
GO_0005925 | Cellular component | focal adhesion |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0120297 | Molecular function | histone dopaminyltransferase activity |
GO_0008233 | Molecular function | peptidase activity |
GO_0003810 | Molecular function | protein-glutamine gamma-glutamyltransferase activity |
GO_0120299 | Molecular function | peptide histaminyltransferase activity |
GO_0050568 | Molecular function | protein-glutamine glutaminase activity |
GO_0120295 | Molecular function | histone serotonyltransferase activity |
GO_0120298 | Molecular function | peptide noradrenalinyltransferase activity |
GO_0005525 | Molecular function | GTP binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TGM2 |
Protein name | Tissue transglutaminase (EC 2.3.2.13) TGM2 protein Protein-glutamine gamma-glutamyltransferase 2 (EC 2.3.2.13) (Erythrocyte transglutaminase) (Heart G alpha(h)) (hhG alpha(h)) (Isopeptidase TGM2) (EC 3.4.-.-) (Protein G alpha(h)) (G(h)) (Protein-glutamine deamidase TGM2) (EC 3.5.1.44) (Protein-glutamine dopaminyltransferase TGM2) (EC 2.3.1.-) (Protein-glutamine histaminyltransferase TGM2) (EC 2.3.1.-) (Protein-glutamine noradrenalinyltransferase TGM2) (EC 2.3.1.-) (Protein-glutamine serotonyltransferase TGM2) (EC 2.3.1.-) (Tissue transglutaminase) (tTG) (tTgase) (Transglutaminase C) (TG(C)) (TGC) (TGase C) (Transglutaminase H) (TGase H) (Transglutaminase II) (TGase II) (Transglutaminase-2) (TG2) (TGase-2) (hTG2) Transglutaminase 2 |
Synonyms | |
Description | FUNCTION: Calcium-dependent acyltransferase that catalyzes the formation of covalent bonds between peptide-bound glutamine and various primary amines, such as gamma-amino group of peptide-bound lysine, or mono- and polyamines, thereby producing cross-linked or aminated proteins, respectively . Involved in many biological processes, such as bone development, angiogenesis, wound healing, cellular differentiation, chromatin modification and apoptosis . Acts as a protein-glutamine gamma-glutamyltransferase by mediating the cross-linking of proteins, such as ACO2, HSPB6, FN1, HMGB1, RAP1GDS1, SLC25A4/ANT1, SPP1 and WDR54 . Under physiological conditions, the protein cross-linking activity is inhibited by GTP; inhibition is relieved by Ca(2+) in response to various stresses . When secreted, catalyzes cross-linking of proteins of the extracellular matrix, such as FN1 and SPP1 resulting in the formation of scaffolds . Plays a key role during apoptosis, both by (1) promoting the cross-linking of cytoskeletal proteins resulting in condensation of the cytoplasm, and by (2) mediating cross-linking proteins of the extracellular matrix, resulting in the irreversible formation of scaffolds that stabilize the integrity of the dying cells before their clearance by phagocytosis, thereby preventing the leakage of harmful intracellular components . In addition to protein cross-linking, can use different monoamine substrates to catalyze a vast array of protein post-translational modifications: mediates aminylation of serotonin, dopamine, noradrenaline or histamine into glutamine residues of target proteins to generate protein serotonylation, dopaminylation, noradrenalinylation or histaminylation, respectively . Mediates protein serotonylation of small GTPases during activation and aggregation of platelets, leading to constitutive activation of these GTPases (By similarity). Plays a key role in chromatin organization by mediating serotonylation and dopaminylation of histone H3 . Catalyzes serotonylation of 'Gln-5' of histone H3 (H3Q5ser) during serotonergic neuron differentiation, thereby facilitating transcription . Acts as a mediator of neurotransmission-independent role of nuclear dopamine in ventral tegmental area (VTA) neurons: catalyzes dopaminylation of 'Gln-5' of histone H3 (H3Q5dop), thereby regulating relapse-related transcriptional plasticity in the reward system . Regulates vein remodeling by mediating serotonylation and subsequent inactivation of ATP2A2/SERCA2 (By similarity). Also acts as a protein deamidase by mediating the side chain deamidation of specific glutamine residues of proteins to glutamate . Catalyzes specific deamidation of protein gliadin, a component of wheat gluten in the diet . May also act as an isopeptidase cleaving the previously formed cross-links . Also able to participate in signaling pathways independently of its acyltransferase activity: acts as a signal transducer in alpha-1 adrenergic receptor-mediated stimulation of phospholipase C-delta (PLCD) activity and is required for coupling alpha-1 adrenergic agonists to the stimulation of phosphoinositide lipid metabolism . .; FUNCTION: [Isoform 2]: Has cytotoxic activity: is able to induce apoptosis independently of its acyltransferase activity. . |
Accessions | P21980 A2A2A0 Q9BXQ0 A2A299 ENST00000453095.1 Q6DKH2 ENST00000373403.7 ENST00000361475.7 [P21980-1] |